Ophthotech Announces the Publication of Fovista® in Combination with Lucentis® Phase 2b Study Results in Ophthalmology®, the Journal of the American Academy of Ophthalmology

by Business Wire • 2016/10/31 • 0 Comments

NEW YORK--(BUSINESS WIRE)--Ophthotech announced that the Phase 2b study results of Fovista®, the Company's anti-PDGF agent, have been published online in Ophthalmology®, the journal of the American Academy of Ophthalmology.

← iStent® Trabecular Micro-Bypass Stent Reduced IOP and Medication Use in Predominately Hispanic Glaucoma Patient Population, According to Published Study

Make the Diagnosis: Astounding Optics →

Post navigation